United Therapeutics (UTHR) Common Equity (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Common Equity data on file, last reported at $5.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 13.31% year-over-year to $5.9 billion; the trailing twelve-month figure through Mar 2026 stood at $5.9 billion (down 13.31% YoY), and the FY2025 full-year result was $7.1 billion, up 10.12% from the prior year.
• Common Equity retreated to $5.9 billion in Q1 2026, from $7.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $7.2 billion in Q2 2025 to a low of $63.0 million in Q3 2024.
• A 5-year average of $5.4 billion and a median of $5.7 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 98.9% in 2024 and soared 10360.63% in 2025, its largest moves.
• Tracing UTHR's Common Equity over 5 years: stood at $4.8 billion in 2022, then rose by 24.77% to $6.0 billion in 2023, then grew by 7.67% to $6.4 billion in 2024, then gained by 10.12% to $7.1 billion in 2025, then retreated by 16.84% to $5.9 billion in 2026.
• Business Quant data shows UTHR's Common Equity at $5.9 billion in Q1 2026, $7.1 billion in Q4 2025, and $6.6 billion in Q3 2025.